Development and validation of an immunoassay for quantification of NCAM-1 in human plasma

被引:2
|
作者
Guven, Arcan [1 ]
Gray, Kayleigh [1 ]
Peng, Kuan-Wei [1 ]
Klotz, Allison [1 ]
Kellogg, Mark D. [1 ,2 ,3 ]
Narain, Niven R. [1 ]
Kiebish, Michael A. [1 ]
机构
[1] BERG, 500 Old Connecticut Path, Framingham, MA 01701 USA
[2] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA
[3] Boston Childrens Hosp, Dept Lab Med, 300 Longwood Ave, Boston, MA 02115 USA
关键词
NCAM-1; Biomarker; Assay development; Assay validation; Immunoassay; Ligand binding assay; NK CELL; CD56; LEUKEMIA; ANTIGEN; EXPRESSION;
D O I
10.1016/j.jpba.2021.113981
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Background: Neural Cell Adhesion Molecule 1 (NCAM-1), a multifunctional member of the immunoglobulin superfamily, is expressed on the surface of neurons, glia, skeletal muscle, and natural killer cells. NCAM-1 has been implicated as having a role in cell-cell adhesion, involved in development of the nervous system, and for cells involved in the expansion of T cells and dendritic cells which play an important role in immune surveillance. Sensitive and specific methods to quantify non-surface bound NCAM-1 are not available. Method: A sandwich ligand binding assay was developed for quantification of NCAM-1 in plasma and validated using an electro-chemiluminescent (ECL) technology. Results: The data presented here demonstrated that the validated method met all prespecified criteria for precision, linearity, and accuracy in the range of 62.5 ng/mL to 4000.0 ng/mL, the range believed to be most relevant for plasma. The bioanalytical validation of the assay established the inter-assay coefficient of variation <8 % for calibration points, <2 % for high quality control (HQC), <8 % for medium quality control (MQC) and <19 % for low quality control (LQC) samples. Purified NCAM-1 spike-recovery experiment in plasma was used to determine assay accuracy; nominal concentrations (%) of NCAM-1 ranged from 91 % to 112 % for high and low spike level, respectively. Assay performance was subsequently evaluated for parallelism, selectivity, interference, and stability. Conclusion: NCAM-1 assay has been developed and validated in human plasma and met all assay validation parameters pre-determined during development. Clinical testing of human plasma samples indicated that NCAM-1 does not seem to be influenced by age and was slightly influenced by gender. NCAM-1 assay has potential to be used as a biomarker assay once the assay is subjected to appropriate clinical assessment and diagnostic thresholds are established. (C) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma
    Casals, Gregori
    Hernandez, Cristina
    Hidalgo, Susana
    Morales, Blai
    Lopez-Pua, Yolanda
    Castro, Pedro
    Fortuna, Virginia
    Antonio Martinez, Jose
    Brunet, Merce
    CLINICAL BIOCHEMISTRY, 2014, 47 (16-17) : 223 - 227
  • [22] Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma
    Cozzi, Valeria
    Charbe, Nitin
    Baldelli, Sara
    Castoldi, Simone
    Atzori, Chiara
    Cattaneo, Dario
    Clementi, Emilio
    THERAPEUTIC DRUG MONITORING, 2016, 38 (03) : 407 - 413
  • [23] Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma
    Li, Ning
    Han, Xiaohong
    Du, Ping
    Song, Yuanyuan
    Hu, Xingsheng
    Yang, Sheng
    Shi, Yuankai
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2014, 406 (06) : 1799 - 1805
  • [24] Development and validation of a LC-HRMS method for the quantification of cannabinoids and their metabolites in human plasma
    Mohamed, Mahmoud Kamel
    Takyi-Williams, John
    Baudot, Bertrand
    Grobler, Anne
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 159
  • [25] Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
    Challenger, Elizabeth
    Penchala, Sujan Dilly
    Hale, Colin
    Fitzgerald, Richard
    Walker, Lauren
    Reynolds, Helen
    Chiong, Justin
    Fletcher, Tom
    Khoo, Saye
    Else, Laura
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 233
  • [26] Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma
    Blanchet, Benoit
    Saboureau, Carole
    Benichou, Anne Sophie
    Billemont, Bertrand
    Taieb, Fabrice
    Ropert, Stanislas
    Dauphin, Alain
    Goldwasser, Francois
    Tod, Michel
    CLINICA CHIMICA ACTA, 2009, 404 (02) : 134 - 139
  • [27] DEVELOPMENT AND VALIDATION OF AN AUTOMATED PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY METHOD FOR THE MEASUREMENT OF HUMAN PLASMA C1Q
    BORQUE, L
    OLIVAN, V
    IGUAZ, F
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1995, 9 (05) : 302 - 307
  • [28] Expression of ICAM-1, ICAM-2, NCAM-1 and VCAM-1 by human synovial cells exposed to Borrelia burgdorferi in vitro
    Sunit K. Singh
    Verena Baar
    Henner Morbach
    Hermann J. Girschick
    Rheumatology International, 2006, 26 : 818 - 827
  • [29] Development and validation of a novel multiplex immunoassay for the simultaneous quantification of food allergen proteins
    Hindley, James
    Filep, Stephanie
    Reid-Black, Kristina
    Lee, Jessica
    Murphy, Brian
    Block, Denise
    Oliver, Maria
    Kuklinska-Pijanka, Anna
    Bermingham, Max
    Chapman, Martin
    CLINICAL AND EXPERIMENTAL ALLERGY, 2019, 49 (12): : 1651 - 1651
  • [30] Expression of ICAM-1, ICAM-2, NCAM-1 and VCAM-1 by human synovial cells exposed to Borrelia burgdorferi in vitro
    Singh, Sunit K.
    Baar, Verena
    Morbach, Henner
    Girschick, Hermann J.
    RHEUMATOLOGY INTERNATIONAL, 2006, 26 (09) : 818 - 827